AU2018372889A1 - Halo-allylamine SSAO/VAP-1 inhibitor and use thereof - Google Patents
Halo-allylamine SSAO/VAP-1 inhibitor and use thereof Download PDFInfo
- Publication number
- AU2018372889A1 AU2018372889A1 AU2018372889A AU2018372889A AU2018372889A1 AU 2018372889 A1 AU2018372889 A1 AU 2018372889A1 AU 2018372889 A AU2018372889 A AU 2018372889A AU 2018372889 A AU2018372889 A AU 2018372889A AU 2018372889 A1 AU2018372889 A1 AU 2018372889A1
- Authority
- AU
- Australia
- Prior art keywords
- independently selected
- membered
- hydrogen
- substituent
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CCCC*(C)*C(C)I[C@](C)C(C(C)N(*)*)=C(C)* Chemical compound CCCC*(C)*C(C)I[C@](C)C(C(C)N(*)*)=C(C)* 0.000 description 15
- DGGKXQQCVPAUEA-UHFFFAOYSA-N C(C1)C2NC1CCC2 Chemical compound C(C1)C2NC1CCC2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 2
- TXTILTRMBJQAPB-ALCCZGGFSA-N CC(C)(C)OC(NC/C(/CBr)=C\F)=O Chemical compound CC(C)(C)OC(NC/C(/CBr)=C\F)=O TXTILTRMBJQAPB-ALCCZGGFSA-N 0.000 description 2
- UMRZSTCPUPJPOJ-UHFFFAOYSA-N C(C1)C2CC1CC2 Chemical compound C(C1)C2CC1CC2 UMRZSTCPUPJPOJ-UHFFFAOYSA-N 0.000 description 1
- JLVDVIXDYDGVLS-UHFFFAOYSA-N C(C1)C2COC1C2 Chemical compound C(C1)C2COC1C2 JLVDVIXDYDGVLS-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-N C(C1)C2OC1CNC2 Chemical compound C(C1)C2OC1CNC2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 1
- CYVWLTUTISTLLO-UHFFFAOYSA-N C1=CC2=CC=CC1O2 Chemical compound C1=CC2=CC=CC1O2 CYVWLTUTISTLLO-UHFFFAOYSA-N 0.000 description 1
- MRIDCFUOJMFLQC-MDWZMJQESA-N CC(C)(C)OC(NC/C(/COc(cc1)cc(CN2)c1C2=C)=C\F)=O Chemical compound CC(C)(C)OC(NC/C(/COc(cc1)cc(CN2)c1C2=C)=C\F)=O MRIDCFUOJMFLQC-MDWZMJQESA-N 0.000 description 1
- AWVKGQFXLGZAHG-WUXMJOGZSA-N CC(C)(C)OC(NC/C(/COc(cc1CN2)ncc1C2=C)=C\F)=O Chemical compound CC(C)(C)OC(NC/C(/COc(cc1CN2)ncc1C2=C)=C\F)=O AWVKGQFXLGZAHG-WUXMJOGZSA-N 0.000 description 1
- INVHCBCQWKREDA-SNAWJCMRSA-N CC/C(/CBr)=C\F Chemical compound CC/C(/CBr)=C\F INVHCBCQWKREDA-SNAWJCMRSA-N 0.000 description 1
- NABPJCARWTVSTH-JLHYYAGUSA-N CC/C(/COc(cc1)cc(CCN2C(C)C)c1C2=O)=C\F Chemical compound CC/C(/COc(cc1)cc(CCN2C(C)C)c1C2=O)=C\F NABPJCARWTVSTH-JLHYYAGUSA-N 0.000 description 1
- BYZMNPMLACHWMB-KPKJPENVSA-N CC/C(/COc(nc1)cc(CN2C3CC3)c1C2=C)=C\F Chemical compound CC/C(/COc(nc1)cc(CN2C3CC3)c1C2=C)=C\F BYZMNPMLACHWMB-KPKJPENVSA-N 0.000 description 1
- AANSSNQOLRAQQZ-BJMVGYQFSA-N CNC/C(/COc1cc(CN(C2CC2)C2=O)c2nc1)=C\F Chemical compound CNC/C(/COc1cc(CN(C2CC2)C2=O)c2nc1)=C\F AANSSNQOLRAQQZ-BJMVGYQFSA-N 0.000 description 1
- BLSBHXARALESMK-UHFFFAOYSA-N CNc(cc1)nc(CN2C3CC3)c1C2=N Chemical compound CNc(cc1)nc(CN2C3CC3)c1C2=N BLSBHXARALESMK-UHFFFAOYSA-N 0.000 description 1
- ZRMUVQCISDPWIS-UHFFFAOYSA-N COC(c(cc1)c(CBr)nc1OC)=O Chemical compound COC(c(cc1)c(CBr)nc1OC)=O ZRMUVQCISDPWIS-UHFFFAOYSA-N 0.000 description 1
- VYSCXJZCARQTGY-UHFFFAOYSA-N COc(cc1)nc(CN2C3CC3)c1C2=O Chemical compound COc(cc1)nc(CN2C3CC3)c1C2=O VYSCXJZCARQTGY-UHFFFAOYSA-N 0.000 description 1
- GSCONURIEUPPTK-UHFFFAOYSA-N C[O-](C)c(cc1CN2)ccc1C2=O Chemical compound C[O-](C)c(cc1CN2)ccc1C2=O GSCONURIEUPPTK-UHFFFAOYSA-N 0.000 description 1
- HTBPXLJKMNBQMS-UHFFFAOYSA-N Cc(cc(nc1)OC)c1Br Chemical compound Cc(cc(nc1)OC)c1Br HTBPXLJKMNBQMS-UHFFFAOYSA-N 0.000 description 1
- VFQZBTDFJLSQCM-UHFFFAOYSA-N Cc1c(C#N)ncc(O)c1 Chemical compound Cc1c(C#N)ncc(O)c1 VFQZBTDFJLSQCM-UHFFFAOYSA-N 0.000 description 1
- UGDSWVXJJFIVAH-UHFFFAOYSA-N Cc1cc(O)cnc1Cl Chemical compound Cc1cc(O)cnc1Cl UGDSWVXJJFIVAH-UHFFFAOYSA-N 0.000 description 1
- CQDFDROFSGYSRE-UHFFFAOYSA-N Nc(nc1CN2C3CC3)ccc1C2=N Chemical compound Nc(nc1CN2C3CC3)ccc1C2=N CQDFDROFSGYSRE-UHFFFAOYSA-N 0.000 description 1
- VZCBZPCYRWHXEY-UHFFFAOYSA-N Oc(cc1)nc(CCN2C3CC3)c1C2=O Chemical compound Oc(cc1)nc(CCN2C3CC3)c1C2=O VZCBZPCYRWHXEY-UHFFFAOYSA-N 0.000 description 1
- DXUCQHPMDOPVSI-UHFFFAOYSA-N Oc(nc1)cc(CCN2C3CC3)c1C2=O Chemical compound Oc(nc1)cc(CCN2C3CC3)c1C2=O DXUCQHPMDOPVSI-UHFFFAOYSA-N 0.000 description 1
- DUGLMATUSUVYMV-UHFFFAOYSA-N c1cc2ccc1[o]2 Chemical compound c1cc2ccc1[o]2 DUGLMATUSUVYMV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711163324 | 2017-11-21 | ||
| CN201711163324.7 | 2017-11-21 | ||
| CN201810081619.8 | 2018-01-29 | ||
| CN201810081619 | 2018-01-29 | ||
| CN201810854213.9 | 2018-07-30 | ||
| CN201810854213 | 2018-07-30 | ||
| PCT/CN2018/116606 WO2019101086A1 (zh) | 2017-11-21 | 2018-11-21 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018372889A1 true AU2018372889A1 (en) | 2020-06-11 |
Family
ID=66601549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018372889A Abandoned AU2018372889A1 (en) | 2017-11-21 | 2018-11-21 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11649233B2 (https=) |
| EP (1) | EP3715341A4 (https=) |
| JP (1) | JP7305196B2 (https=) |
| KR (1) | KR20200094168A (https=) |
| CN (1) | CN109810041B (https=) |
| AU (1) | AU2018372889A1 (https=) |
| CA (1) | CA3083020A1 (https=) |
| TW (1) | TWI721335B (https=) |
| WO (1) | WO2019101086A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109810041B (zh) | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
| CN109988109B (zh) * | 2017-12-29 | 2020-12-29 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其用途 |
| KR20190110736A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR20190110740A (ko) | 2018-03-21 | 2019-10-01 | 주식회사유한양행 | 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| CN110938059A (zh) * | 2018-09-25 | 2020-03-31 | 上海轶诺药业有限公司 | 胺基脲敏感性胺氧化酶抑制剂制备及其应用 |
| MX2021003559A (es) | 2018-09-28 | 2021-08-24 | Acucela Inc | Inhibidores de vap-1. |
| CA3114166A1 (en) | 2018-09-28 | 2020-04-02 | Acucela Inc. | Inhibitors of vap-1 |
| US12213970B2 (en) | 2018-10-29 | 2025-02-04 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| KR102812426B1 (ko) | 2018-10-29 | 2025-05-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도 |
| TWI835945B (zh) | 2018-12-14 | 2024-03-21 | 南韓商柳韓洋行股份有限公司 | 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物 |
| TW202039486A (zh) * | 2018-12-14 | 2020-11-01 | 南韓商柳韓洋行股份有限公司 | 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物 |
| AU2020206477B2 (en) * | 2019-01-11 | 2022-11-10 | Transthera Sciences (Nanjing), Inc. | Haloallylamine compounds and application thereof |
| AU2020377093B2 (en) | 2019-10-29 | 2026-02-26 | Eccogene Inc. | SSAO inhibitors and use thereof |
| CN112876419A (zh) * | 2019-11-29 | 2021-06-01 | 四川科伦博泰生物医药股份有限公司 | 烯丙胺衍生物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004502682A (ja) * | 2000-07-05 | 2004-01-29 | バイオティ セラピーズ コーポレイション | 銅含有アミン・オキシダーゼの阻害剤 |
| CN1863763A (zh) * | 2003-08-08 | 2006-11-15 | 拉卓拉药物公司 | 用于治疗疾病的氨基脲敏感性胺氧化酶(ssao)和vap－1介导的粘着的抑制剂 |
| AU2005216955A1 (en) * | 2004-02-25 | 2005-09-09 | La Jolla Pharmaceutical Company | Amines and amides for the treatment of diseases |
| CN1921841A (zh) * | 2004-02-25 | 2007-02-28 | 拉卓拉药物公司 | 用于治疗疾病的胺和酰胺类化合物 |
| US20070293548A1 (en) * | 2006-03-31 | 2007-12-20 | Wang Eric Y | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases |
| CN101917845A (zh) * | 2007-11-21 | 2010-12-15 | 法马克西斯制药公司 | Ssao/vap-1的卤代烯丙胺抑制剂及其用途 |
| AU2013255103B2 (en) * | 2012-05-02 | 2016-09-29 | Syntara Limited | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| US20200087248A1 (en) * | 2017-04-28 | 2020-03-19 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Fluoroallylamine Derivative And Use Thereof |
| CN109251166B (zh) * | 2017-07-13 | 2021-11-05 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
| WO2019024924A1 (zh) * | 2017-08-04 | 2019-02-07 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
| CN109810041B (zh) | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
| CN109988106B (zh) * | 2017-12-29 | 2023-03-31 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
| CN109988093B (zh) * | 2017-12-29 | 2023-04-07 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
-
2018
- 2018-11-20 CN CN201811386564.8A patent/CN109810041B/zh active Active
- 2018-11-21 US US15/733,125 patent/US11649233B2/en active Active
- 2018-11-21 AU AU2018372889A patent/AU2018372889A1/en not_active Abandoned
- 2018-11-21 CA CA3083020A patent/CA3083020A1/en active Pending
- 2018-11-21 KR KR1020207017780A patent/KR20200094168A/ko not_active Ceased
- 2018-11-21 JP JP2020527927A patent/JP7305196B2/ja active Active
- 2018-11-21 TW TW107141484A patent/TWI721335B/zh not_active IP Right Cessation
- 2018-11-21 EP EP18881966.8A patent/EP3715341A4/en not_active Withdrawn
- 2018-11-21 WO PCT/CN2018/116606 patent/WO2019101086A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TWI721335B (zh) | 2021-03-11 |
| JP7305196B2 (ja) | 2023-07-10 |
| WO2019101086A1 (zh) | 2019-05-31 |
| EP3715341A1 (en) | 2020-09-30 |
| CN109810041B (zh) | 2023-08-15 |
| US11649233B2 (en) | 2023-05-16 |
| KR20200094168A (ko) | 2020-08-06 |
| CA3083020A1 (en) | 2019-05-31 |
| US20210070750A1 (en) | 2021-03-11 |
| JP2021504317A (ja) | 2021-02-15 |
| TW201925173A (zh) | 2019-07-01 |
| EP3715341A4 (en) | 2020-11-25 |
| CN109810041A (zh) | 2019-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018372889A1 (en) | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | |
| AU2020341681B2 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
| JP7644517B2 (ja) | Ｋｒａｓ突然変異型タンパク質阻害剤 | |
| AU2020214404B2 (en) | Immunomodulators, compositions and methods thereof | |
| AU2018386298B2 (en) | Inhibitors of fibroblast activation protein | |
| JP7282397B2 (ja) | Ｔａｍファミリーキナーゼ／及びｃｓｆ１ｒキナーゼ阻害剤及びその用途 | |
| JP7097373B2 (ja) | キナーゼ阻害剤としてのアミノトリアゾロピリジン | |
| AU2020329207B2 (en) | Compounds for inhibition of alpha 4 beta 7 integrin | |
| AU2018361249B2 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| CA3115830A1 (en) | Compounds for inhibition of .alpha.4.beta.7 integrin | |
| CA3181537A1 (en) | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors | |
| WO2019183186A1 (en) | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| CA2890929A1 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses | |
| CA3241338A1 (en) | Parp inhibitor, pharmaceutical composition comprising same, and use thereof | |
| JP7323637B2 (ja) | 置換複素環式アミド化合物、その調製方法、及びその医薬的使用 | |
| CN118076597A (zh) | 一种氮杂喹啉酮类衍生物、其制备方法及用途 | |
| WO2022241172A1 (en) | Substituted heterocyclic compounds | |
| JP2022521536A (ja) | イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用 | |
| AU2019408406B2 (en) | Disubstituted alkyne derivatives | |
| CA3181351A1 (en) | Nampt modulators | |
| KR20180025928A (ko) | 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체 | |
| HK40028252A (en) | Halo-allylamine ssao/vap-1 inhibitor and use thereof | |
| CN110724076B (zh) | 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途 | |
| HK40041650A (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |